The impact of generic substitution on the turnover and gross margin of pharmaceutical companies a survey 1 year and 5 years after the introduction of generic substitution in Finland

Health Policy

Volumn 92, Issue 2-3, 2009, Pages 116-123

  Timonen, Johanna ^a   Karttunen, Pekka ^b   Bengtström, Marina ^c   Ahonen, Riitta ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b VIII Pharmacy of Kuopio   (Finland)

^c Pharma Industry Finland   (Finland)

Author keywords

Generic substitution; Gross margin per cent; Pharmaceutical company; Turnover

Indexed keywords

GENERIC DRUG;

ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC ASPECT; FINLAND; HEALTH CARE POLICY; PHARMACY; PROFIT; QUESTIONNAIRE;

COMMERCE; CROSS-SECTIONAL STUDIES; DRUG INDUSTRY; DRUG PRESCRIPTIONS; DRUGS, GENERIC; ECONOMIC COMPETITION; FINLAND; QUESTIONNAIRES;

EID: 69249235556     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2009.03.004     Document Type: Article

References (32)

1. Simoens S., and De Coster S. Sustaining generic medicines markets in Europe (2006), Research Centre for Pharmaceutical Care and Pharmaco-economics Katholieke Universiteit Leuven, Belgia
2. Kjoenniksen I., Lindbaek M., and Granas A.G. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharmacy World and Science 28 (2006) 284-289
3. Andersson K., Berström G., Petzold M.G., and Carlsten A. Impact of a generic substitution reform on patients' and society expenditure for pharmaceuticals. Health Policy 81 (2007) 376-384
4. Heikkilä R., Mäntyselkä P., Hartikainen-Herranen K., and Ahonen R. Customers' and physicians' opinions of and experiences with generic substitution during the first year in Finland. Health Policy 82 (2007) 366-374
5. Congressional Budget Office. How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. The Congress of the United States, Congressional Budget Office; 1998.
6. Buzzelli C., Kangasharju A., Linnosmaa I., and Valtonen H. Impact of generic substitution on pharmaceuticals prices and expenditures in OECD countries. Journal of Pharmaceutical Finance, Economics and Policy 15 (2006) 41-63
7. Aalto-Setälä V., Kanerva R., and Bell S. Drug cost development of citalopram and fluoxetine following the introduction of generic substitution. International Journal of Pharmaceutical Medicines 21 (2007) 363-368
8. Aalto-Setälä V. The impact of generic substitution on price competition in Finland. The European Journal of Health Economics 9 (2008) 185-191
9. Andersson K.A., Petzold M.G., Allebeck P., and Carlsten A. Influence of mandatory generic substitution on pharmaceutical sales patterns: a national study over five years. BMC Health Services Research 8 (2008) 50
10. The Social Insurance Institution of Finland. Generic substitution, http://www.kela.fi/in/internet/english.nsf/NET/220703130721MP?openDocume nt; 2008.
11. National Agency for Medicines. Criteria used in compiling the list, http://www.nam.fi/medicines/substitutable_medicinal_products/criteria_us ed; 2008.
12. Malminiemi K., and Tokola O. Luettelo vaihtokelpoisista lääkevalmisteista. Tabu 11 (2003) 13-14
13. National Agency for Medicines. Vaihtokelpoisten lääkevalmisteiden luettelo October 1, 2008-December 31, 2008, http://www.laakelaitos.fi/ajankohtaista/3/vaihtokelpoisten_laakevalmiste iden_luettelo_1_10_2008_31_12_2008; 2008.
14. Ministry of Social Affairs and Health. Lääkkeiden viitehintajärjestelmää selvittäneen työryhmän muistio. Helsinki; 2007.
15. Pharma Industry Finland. Pharma Facts Finland 2008, http://www.pif.fi/tiedostot/LT_Numeroina08_eng_final(1).pdf; 2008.
16. Pharma Industry Finland. The Finnish pharmaceutical market, http://www.pif.fi/page.php? page_id=214; 2008.
17. Finnish Pharmaceutical data Ltd.; 2008.
18. Data of Pharma Industry Finland; 2009.
19. Vogler S, Habl C, Leopold C, Rosian-Schikuta I, de Joncheere K, Thomsen T. PPRI--pharmaceutical pricing and reimbursement information report. Vienna; 2008.
20. Suh D., Manning Jr. W.G., Schondelmeyer S., and Hadsall R.S. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry. Health Services Research 35 (2000) 529-547
21. Hudson J. Generic take-up in the pharmaceutical market following patent expiry-a multi-country study. International Review of Law and Economics 20 (2000) 205-221
22. Aronsson T., Bergman M., and Rudholm N. The impact of generic drug competition on brand name market shares-evidence from micro data. Review of Industrial Organization 19 (2001) 425-435
23. Hallituksen esitys Eduskunnalle lääkelain ja sairausvakuutuslain muuttamisesta. HE 165/2002, http://www.eduskunta.fi/triphome/bin/akxhref2.sh?{KEY}=HE+165/2002; 2002.
24. Kangasharju A., Linnosmaa I., Pudas H., and Valtonen H. Geneerinen substituutio, markkinarakenne ja hinnat Suomen lääkemarkkinoilla. In: Klavus J. (Ed). Terveystaloustiede 2007 (2007), Stakes, Helsinki 33-35
25. Jormanainen V., Kannisto H., and Mäntyranta T. Pharmacy and hospital market performance indicators in Finland 1995-2007. Poster presented in ISPOR Eleventh Annual European Congress. November 8-11, 2008, Athens, Greece (2008)
26. Paldan M. Lääkevaihto vuonna 2005: Vaihtokelpoisten lääkepakkausten hinnat laskivat keskimäärin 8%. Suomen Lääkärilehti 61 (2006) 2496-2498
27. Frank R.G., and Salkever D.S. Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy 6 (1997) 75-90
28. Lexchin J. The effect of generic competition on the price of brand-name drug. Health Policy 68 (2004) 47-54
29. Harzing A. Cross-national industrial mail surveys: why do response rates differ between countries?. Industrial Marketing Management 29 (2000) 243-254
30. Geitona M., Kyriopoulos J., Zavras D., and Hatzikou M. Generics market in Greece: the pharmaceutical industry's beliefs. Health Policy 79 (2006) 35-48
31. Liljeblom E, Vaihekoski M. Owners' way or the highway: short term expectations and owner impatience. Hanken's Research Report 62, http://papers.ssrn.com/sol3/papers.cfm?abstract_id=955808; 2007.
32. Ghislandi S., Krulichova I., and Garattini L. Pharmaceutical policy in Italy: towards a structural change?. Health Policy 72 (2005) 53-63